Mediated strategies to enhance TRIM8 that in turn activates the p53 tumor suppressor function and blunt the oncogenic activity of ΔNp63α may offer therapeutic benefits and are likely to improve the management of chemoresistant tumors. Here, TP53 is linked to neoplasm.